The deal offers a substantial premium and has committed financing, making it highly likely to close. Shareholders should vote FOR the merger. The stock currently trades near the offer price, limiting upside but with downside risk if the deal fails. Monitor regulatory approvals and the shareholder vote on July 23.
Price Chart
Executive Summary
Organon & Co. shareholders are being asked to vote on the proposed acquisition by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash, representing a ~103% premium to the unaffected stock price. The board unanimously recommends approval, and Morgan Stanley has issued a fairness opinion. The special meeting is scheduled for July 23, 2026, with closing expected in early 2027.
Key Financial Metrics
Key Facts
- $14.00 per share cash consideration, ~103% premium to unaffected closing price on April 9, 2026
- Board unanimously recommends voting FOR the merger agreement
- Morgan Stanley & Co. LLC provided a fairness opinion concluding the consideration is fair from a financial point of view
- Special meeting of stockholders set for July 23, 2026; vote requires majority of outstanding shares
- Expected closing in early 2027, subject to shareholder approval and regulatory clearances
- Termination fee of $120 million payable by Organon under certain circumstances
- Sun Pharma USA has obtained a committed senior secured bridge loan facility of up to $12 billion; no financing condition
Financial Impact
Shareholders to receive $14.00 per share in cash, totaling approximately $3.68 billion for outstanding shares
Risk Factors
- Failure to obtain required regulatory approvals (antitrust, foreign investment) could delay or block the merger
- Shareholder vote requires majority of outstanding shares; failure to achieve quorum or approval could terminate the deal
- Termination fee of $120 million may be triggered if Organon accepts a superior proposal or board changes recommendation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001193125-26-273323 |
| Document: d15298ddefm14a.htm | 0001193125-26-273323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.74 (−0.44%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.74 (−1.40%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.74 (+1.85%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.74 (+2.38%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.74 (+2.16%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.74 (+2.81%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.74 (+3.74%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.74 (−3.74%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers